S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Will This Be the Worst U.S. Crisis Ever? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Will This Be the Worst U.S. Crisis Ever? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Will This Be the Worst U.S. Crisis Ever? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Will This Be the Worst U.S. Crisis Ever? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
NYSE:MD

Pediatrix Medical Group - MD Stock Forecast, Price & News

$21.04
+0.39 (+1.89%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$20.51
$21.11
50-Day Range
$18.54
$23.64
52-Week Range
$17.17
$35.67
Volume
670,186 shs
Average Volume
619,267 shs
Market Capitalization
$1.84 billion
P/E Ratio
21.47
Dividend Yield
N/A
Price Target
$25.17

Pediatrix Medical Group MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
19.6% Upside
$25.17 Price Target
Short Interest
Healthy
4.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.16mentions of Pediatrix Medical Group in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.51%
From $1.73 to $1.86 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

644th out of 1,108 stocks

Hospitals Industry

3rd out of 3 stocks

MD stock logo

About Pediatrix Medical Group (NYSE:MD) Stock

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. BMO Capital Markets reduced their price target on shares of Pediatrix Medical Group from $25.00 to $23.00 and set a "market perform" rating on the stock in a research report on Wednesday. StockNews.com lowered shares of Pediatrix Medical Group from a "buy" rating to a "hold" rating in a report on Monday, May 2nd. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Pediatrix Medical Group from $24.00 to $16.00 in a report on Tuesday, May 10th. Mizuho dropped their price objective on shares of Pediatrix Medical Group from $28.00 to $23.00 in a report on Monday, May 2nd. Finally, TheStreet lowered shares of Pediatrix Medical Group from a "b-" rating to a "c+" rating in a report on Wednesday, April 13th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $25.17.

Pediatrix Medical Group Stock Up 1.9 %

MD Stock traded up $0.39 during midday trading on Wednesday, hitting $21.04. The company's stock had a trading volume of 670,186 shares, compared to its average volume of 619,267. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.39 and a quick ratio of 1.39. Pediatrix Medical Group has a twelve month low of $17.17 and a twelve month high of $35.67. The company's fifty day moving average price is $21.37 and its 200 day moving average price is $22.04. The stock has a market capitalization of $1.84 billion, a P/E ratio of 21.47, a PEG ratio of 1.22 and a beta of 1.84.

Pediatrix Medical Group (NYSE:MD - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.04. Pediatrix Medical Group had a net margin of 4.30% and a return on equity of 16.15%. The firm had revenue of $486.00 million for the quarter, compared to analyst estimates of $491.54 million. During the same period in the previous year, the business earned $0.36 EPS. The company's revenue was up 2.7% compared to the same quarter last year. As a group, equities research analysts predict that Pediatrix Medical Group will post 1.73 EPS for the current year.

Receive MD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pediatrix Medical Group and its competitors with MarketBeat's FREE daily newsletter.

MD Stock News Headlines

Pediatrix Medical Group Inc
Mednax (MD) Q2 Earnings Match Estimates
Pediatrix Medical Group Reports Second Quarter Results
See More Headlines
Receive MD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pediatrix Medical Group and its competitors with MarketBeat's FREE daily newsletter.

MD Company Calendar

Last Earnings
8/04/2022
Today
8/10/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Hospitals
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
58502B10
Employees
5,000
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$25.17
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+19.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$130.96 million
Pretax Margin
5.70%

Debt

Sales & Book Value

Annual Sales
$1.91 billion
Cash Flow
$2.05 per share
Book Value
$10.37 per share

Miscellaneous

Free Float
84,294,000
Market Cap
$1.84 billion
Optionable
Optionable
Beta
1.84

Social Links


Key Executives

  • Mr. Mark S. Ordan (Age 63)
    CEO & Director
    Comp: $3.35M
  • Dr. Roger J. Medel M.D. (Age 75)
    Co-Founder & Director
    Comp: $50.99k
  • Mr. C. Marc Richards (Age 51)
    Exec. VP & CFO
    Comp: $1.29M
  • Mr. John C. Pepia (Age 59)
    Sr. VP & Chief Accounting Officer
    Comp: $931.2k
  • Mr. Dominic J. Andreano (Age 53)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $1.29M
  • Ms. Mary Ann E. Moore (Age 62)
    Exec. VP and Chief Enterprise Risk & Legal Operations Officer
    Comp: $3.21M
  • Dr. James D. Swift M.D.
    Exec. VP & Chief Operating Officer
  • Ms. Cheryl M. VanPattan
    Sr. VP & Chief Information Officer
  • Mr. Charles W. Lynch C.F.A.
    Sr. VP of Fin., Strategy & Investor Relations
  • Ms. Dana Dreher-Rodwell
    VP & Chief Compliance Officer













MD Stock - Frequently Asked Questions

Should I buy or sell Pediatrix Medical Group stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pediatrix Medical Group in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MD, but not buy additional shares or sell existing shares.
View MD analyst ratings
or view top-rated stocks.

What is Pediatrix Medical Group's stock price forecast for 2022?

4 equities research analysts have issued twelve-month price objectives for Pediatrix Medical Group's shares. Their MD share price forecasts range from $16.00 to $31.00. On average, they expect the company's stock price to reach $25.17 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price.
View analysts price targets for MD
or view top-rated stocks among Wall Street analysts.

How have MD shares performed in 2022?

Pediatrix Medical Group's stock was trading at $27.21 at the start of the year. Since then, MD shares have decreased by 22.7% and is now trading at $21.04.
View the best growth stocks for 2022 here
.

Are investors shorting Pediatrix Medical Group?

Pediatrix Medical Group saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,920,000 shares, an increase of 33.0% from the June 15th total of 3,700,000 shares. Based on an average daily trading volume, of 738,900 shares, the days-to-cover ratio is presently 6.7 days. Approximately 5.8% of the shares of the company are short sold.
View Pediatrix Medical Group's Short Interest
.

When is Pediatrix Medical Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our MD earnings forecast
.

How were Pediatrix Medical Group's earnings last quarter?

Pediatrix Medical Group, Inc. (NYSE:MD) released its earnings results on Thursday, August, 4th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.43 by $0.04. The firm earned $486 million during the quarter, compared to analysts' expectations of $491.54 million. Pediatrix Medical Group had a trailing twelve-month return on equity of 16.15% and a net margin of 4.30%. Pediatrix Medical Group's quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.36 EPS.

What is Mark S. Ordan's approval rating as Pediatrix Medical Group's CEO?

6 employees have rated Pediatrix Medical Group Chief Executive Officer Mark S. Ordan on Glassdoor.com. Mark S. Ordan has an approval rating of 34% among the company's employees. This puts Mark S. Ordan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pediatrix Medical Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pediatrix Medical Group investors own include NVIDIA (NVDA), AbbVie (ABBV), QUALCOMM (QCOM), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T), Walt Disney (DIS), Wells Fargo & Company (WFC), Exxon Mobil (XOM) and Advanced Micro Devices (AMD).

What is Pediatrix Medical Group's stock symbol?

Pediatrix Medical Group trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

Who are Pediatrix Medical Group's major shareholders?

Pediatrix Medical Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Granite Investment Partners LLC (0.61%), Foundry Partners LLC (0.17%), Comerica Bank (0.15%), State of Alaska Department of Revenue (0.07%), Yousif Capital Management LLC (0.07%) and SG Americas Securities LLC (0.05%). Insiders that own company stock include John C Pepia, Mark S Ordan, Md Pascal J Goldschmidt, Michael Fernandez, Nicholas J Nikolopoulos, Roger Mack Hinson and Roger Md Medel.
View institutional ownership trends
.

How do I buy shares of Pediatrix Medical Group?

Shares of MD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pediatrix Medical Group's stock price today?

One share of MD stock can currently be purchased for approximately $21.04.

How much money does Pediatrix Medical Group make?

Pediatrix Medical Group (NYSE:MD) has a market capitalization of $1.84 billion and generates $1.91 billion in revenue each year. The company earns $130.96 million in net income (profit) each year or $0.98 on an earnings per share basis.

How many employees does Pediatrix Medical Group have?

The company employs 5,000 workers across the globe.

When was Pediatrix Medical Group founded?

Pediatrix Medical Group was founded in 1979.

How can I contact Pediatrix Medical Group?

Pediatrix Medical Group's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The official website for the company is www.mednax.com. The company can be reached via phone at (954) 384-0175, via email at charles_lynch@mednax.com, or via fax at 954-838-9961.

This page (NYSE:MD) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.